Skip to main content

Recent Advances in the Discovery and Development of Novel HIV-1 NNRTI Platforms: 2006-2008 Update

Buy Article:

$63.00 plus tax (Refund Policy)

Currently, the long-term usage of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in HIV/AIDS patients eventually leads to the development of drug resistance and severe side effect. Therefore, it is imperative to look for the novel NNRTIs with potent and broad spectrum anti-mutant activity that are also safe and have excellent pharmacokinetic profiles. In this article, newly emerging NNRTIs scaffolds in recent three years, together with the underlying strategies for developing new generation HIV-1 NNRTIs with improved resilience to current drug resistant mutants, are reviewed and analysed.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: AIDS; HIV; NNRTIs; drug design; drug resistance; inhibitor

Document Type: Research Article

Affiliations: Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44, West Culture Road, 250012, Jinan, Shandong, P.R. China.

Publication date: 2009-08-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more